Guard Therapeutics International AB (publ) (STO:GUARD)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.004
-0.020 (-1.95%)
Apr 29, 2026, 11:32 AM CET
-92.16%
Market Cap 20.65M
Revenue (ttm) n/a
Net Income (ttm) -108.85M
Shares Out 20.17M
EPS (ttm) -6.04
PE Ratio n/a
Forward PE 0.45
Dividend n/a
Ex-Dividend Date n/a
Volume 7,076
Average Volume 51,472
Open 1.030
Previous Close 1.024
Day's Range 1.004 - 1.030
52-Week Range 0.881 - 27.000
Beta -0.06
RSI 35.18
Earnings Date May 7, 2026

About STO:GUARD

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. The company’s pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to treat Sepsis. It also develops GTZ peptides, a modified A1M-derived peptides which is in preclinical studies for the treatment of CKD and diabet... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 12
Stock Exchange Nasdaq Stockholm
Ticker Symbol GUARD
Full Company Profile

Financial Performance

Financial Statements

News

Guard Therapeutics International AB Transcript: Study Result

The POINTER phase 2B study of RMC-035 in heart surgery patients did not meet its primary or secondary endpoints, showing no significant benefit over placebo and contrasting with prior AKITA results. Strategic review and full data analysis are ongoing, with likely discontinuation of RMC-035 in this indication.

6 months ago - Transcripts

Guard Therapeutics International AB Transcript: DNB Carnegie Småbolagsdag

A late-stage kidney disease program is nearing key phase 2B data, with strong prior results and FDA fast track status. The company is preparing for phase 3, exploring partnerships, and expects significant commercial and regulatory milestones in the coming months.

8 months ago - Transcripts